Delivering Advanced Therapeutics
CP057 SR Bevacizumab
CP057 is a sustained released injection formulation of Bevacizumab, an anti-VEGF therapy for the treatment of Age-related Macular Degeneration (AMD). Using the CriticalMix technology, CP057 is being developed as a once every three month injection.
AMD is the leading cause of blindness in the over 50’s. It is caused by abnormal blood vessel growth near the macula of the retina. Bleeding, leaking and scarring from these blood vessels eventually cause damage leading to impaired vision. Anti-VEGF therapies are effective at delaying, halting or even reversing this visual loss, but require monthly injections to the eye. These are disliked by patients and have the concomitant risk of serious eye problems such as infections.
CP057 SR Bevacizumab therefore offers a cost effective, safe and effective alternative to current therapies